Pmv Pharmaceuticals, Inc
pmvpharma.comWhat Do They Do?
Develops oral cancer drug candidates that target a tumor-suppressor protein and related cancers for patients with tumors carrying relevant mutations.
10-K for FY2025, filed Mar 6, 2026
Who Are Their Customers?
The therapies are intended for patients with p53-driven cancers; if approved, PMV expects to sell them through its own focused sales organization to oncologists who treat those patients.
10-K for FY2025, filed Mar 6, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$18.1MView ↗
- ▼ −15% (Loss)
- vs −$21.2M in Q2 FY2025
-
Sep 2, 2026
Prices a public offering of shares and warrants
It expects approximately $50.8 million in gross proceeds before discounts, commissions, expenses, and warrant exercises.
Sources
8-K, filed Sep 2, 2026
All of the securities being sold in the offering are being sold by PMV Pharma. The gross proceeds from the offering, before deducting…View ↗
Who Do They Compete With?
Competes with Jacobio Pharmaceuticals, Changchun GeneScience, Frontier Medicines, and Nutshell Therapeutics
10-K for FY2025, filed Mar 6, 2026We are a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53 mutations and other…View ↗
Loading...
